Somborac-Bačura, in 2012 [9] identified that DPP-4 levels were significantly lower in patients with stable COPD than in healthy controls, suggesting its use as a serological biomarker since this enzyme is not affected by smoking, age and other factors related to pathology. Here, DPP4 is linked to chronic obstructive pulmonary disease.